The 44 DCIS showing histopathological neoductgenesis were HER2+/ER− lesions in 55% of the cases, HER2−/ER− in 10%, and ER+ in 35% of the cases while DCIS without signs of neoductgenesis were HER2+/ER− in 15%, HER2−/ER− in 9%, and ER+ in 76% of the cases. The gene discussed is ESR1; the disease is ductal breast carcinoma in situ.